Merck TLR7/8 antagonist patent for coronavirus
Summary
Merck TLR7/8 antagonist patent for coronavirus
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TLR7/8 ANTAGONISTS FOR USE IN THE TREATMENT OF CORONAVIRUS INFECTIONS
Publication EP4149463A1 Kind: A1 Apr 01, 2026
Applicants
Merck Healthcare KGaA
Inventors
DEMARTINO, Julie A.
IPC Classifications
A61K 31/4375 20060101AFI20211119BHEP A61K 31/4709 20060101ALI20211119BHEP A61P 31/14 20060101ALI20211119BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.